Myron Chu

547 total citations
14 papers, 395 citations indexed

About

Myron Chu is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Myron Chu has authored 14 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 11 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Immunology. Recurrent topics in Myron Chu's work include Systemic Lupus Erythematosus Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and T-cell and B-cell Immunology (7 papers). Myron Chu is often cited by papers focused on Systemic Lupus Erythematosus Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and T-cell and B-cell Immunology (7 papers). Myron Chu collaborates with scholars based in United States, United Kingdom and Japan. Myron Chu's co-authors include Damon Bass, David A. Roth, Yoshiya Tanaka, Sang‐Cheol Bae, Jie Zheng, Fengchun Zhang, David Gordon, Regina Kurrasch, David J. Chang and Emilia Quattrocchi and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Drug Discovery Today.

In The Last Decade

Myron Chu

14 papers receiving 388 citations

Peers

Myron Chu

RHEUM

IMMUN

RNMI

PFM

NEURO

Kate Franklyn Australia

D. Licu Switzerland

Francesca Miranda Italy

Judith Sarano Argentina

Risto Perich-Campos Peru

Emily Sutton United Kingdom

Ka Lung Yu China

Michelle Petri United States

DD Gladman Canada

Víctor R. Pimentel-Quiroz Peru

Kate Franklyn Australia

Myron Chu

467 ×1.4

RHEUM

291 ×1.2

IMMUN

173 ×0.9

RNMI

65 ×1.5

PFM

33 ×1.3

NEURO

Citations per year, relative to Myron Chu Myron Chu (= 1×) peers Kate Franklyn

Countries citing papers authored by Myron Chu

Since Specialization

Citations

This map shows the geographic impact of Myron Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Myron Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Myron Chu more than expected).

Fields of papers citing papers by Myron Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Myron Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Myron Chu. The network helps show where Myron Chu may publish in the future.

Co-authorship network of co-authors of Myron Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Myron Chu. A scholar is included among the top collaborators of Myron Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Myron Chu. Myron Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Peeva, Elena, Emma Guttman‐Yassky, Yuji Yamaguchi, et al.. (2025). Unlocking disease insights to facilitate drug development: Pharmaceutical industry–academia collaborations in inflammation and immunology. Drug Discovery Today. 30(3). 104317–104317. 1 indexed citations

Cohen, Stanley M., Jean S. Beebe, Vishala Chindalore, et al.. (2024). A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Research & Therapy. 26(1). 117–117. 5 indexed citations

Carreira, Patrícia, David Fiorentino, Jason C. Sluzevich, et al.. (2023). POS1207 EFFICACY AND SAFETY OF ANTI-IFNΒ-SPECIFIC MONOCLONAL ANTIBODY, PF-06823859, ON MYOSITIS: PHASE 2 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE DERMATOMYOSITIS. Annals of the Rheumatic Diseases. 82. 936–937. 3 indexed citations

Bae, Sang‐Cheol, Damon Bass, Myron Chu, et al.. (2022). The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Arthritis Research & Therapy. 24(1). 46–46. 8 indexed citations

Zheng, Jie, Jieruo Gu, Yin Su, et al.. (2022). Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses. Modern Rheumatology. 33(4). 751–757. 4 indexed citations

Zhang, Fengchun, Jie Zheng, Yang Li, et al.. (2022). Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years. RMD Open. 8(1). e001669–e001669. 11 indexed citations

Tanaka, Yoshiya, Sang‐Cheol Bae, Damon Bass, et al.. (2021). Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 7(2). e001629–e001629. 18 indexed citations

Tanaka, Yoshiya, et al.. (2019). Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Modern Rheumatology. 30(2). 313–320. 12 indexed citations

Zhang, Fengchun, Sang‐Cheol Bae, Damon Bass, et al.. (2018). A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases. 77(3). 355–363. 224 indexed citations

10.

Tanaka, Yoshiya, Damon Bass, Myron Chu, et al.. (2018). Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Modern Rheumatology. 29(3). 452–460. 13 indexed citations

11.

Tanaka, Yoshiya, Damon Bass, Myron Chu, et al.. (2017). 106 Effects of belimumab on corticosteroid use in a pivotal phase iii, randomised, placebo controlled study in subjects with systemic lupus erythematosus in north east asia. A45.2–A46. 2 indexed citations

12.

Quattrocchi, Emilia, Mikkel Østergaard, Peter C. Taylor, et al.. (2016). Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials. PLoS ONE. 11(6). e0157961–e0157961. 18 indexed citations

13.

Crane, Martin M., Maneesh Juneja, Jeffery K. Allen, et al.. (2015). Epidemiology and Treatment of New‐Onset and Established Rheumatoid Arthritis in an Insured US Population. Arthritis Care & Research. 67(12). 1646–1655. 42 indexed citations

14.

Kurrasch, Regina, Judith C. Brown, Myron Chu, et al.. (2013). Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics. The Journal of Rheumatology. 40(7). 1089–1096. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact